Outlook Therapeutics (OTLK) Hits New 12-Month High After Earnings Beat
Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) reached a new 52-week high during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $1.37 and last traded at $1.25, with a volume of 47363 shares. The stock had previously closed at $1.03.
The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.21. The firm had revenue of $1.07 million during the quarter.
Separately, ValuEngine lowered Outlook Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th.
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Read More: Lock-Up Period Expiration
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.